EIF2α phosphorylation as a biomarker of immunogenic cell death

Seminars in Cancer Biology

Volumn 33, Issue , 2015, Pages 86-92

  Kepp, Oliver ^a,b,c   Semeraro, Michaela ^a,b,c   Bravo San Pedro, José Manuel ^a,b,c   Bloy, Norma ^a,b,c   Buqué, Aitziber ^a,b,c   Huang, Xing ^a,b,c   Zhou, Heng ^a,b,c   Senovilla, Laura ^a,b,c   Kroemer, Guido ^a,b,c,d,e,f   Galluzzi, Lorenzo ^a,b,c,e,f  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSERM   (France)

^c CENTRE DE RECHERCHE DES CORDELIERS   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f SORBONNE UNIVERSITÉ   (France)

Author keywords

Apoptosis; ATF4; Autophagy; IRE1 ; PERK

Indexed keywords

ANTHRACYCLINE; BIOLOGICAL MARKER; BORTEZOMIB; CALRETICULIN; CHAPERONE; CYTOKINE; INFLAMMASOME; INITIATION FACTOR 2ALPHA; MONOCLONAL ANTIBODY; OMEGA 3 FATTY ACID; SUNITINIB; TOLL LIKE RECEPTOR; CALRETICULIN, HUMAN; EPITOPE; HEAT SHOCK PROTEIN; INITIATION FACTOR 2; MOLECULAR CHAPERONE GRP78;

ADAPTIVE IMMUNITY; APOPTOSIS; BREAST CANCER; CANCER CELL; CELL ACTIVATION; CELL SURFACE; CELLULAR IMMUNITY; CELLULAR STRESS RESPONSE; ENDOPLASMIC RETICULUM STRESS; HUMAN; IMMUNOBLOTTING; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MOLECULAR MECHANICS; MULTIPLE MYELOMA; NONHUMAN; PROSTATE CARCINOMA; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TUMOR IMMUNITY; UNFOLDED PROTEIN RESPONSE; ANIMAL; ANTIGEN PRESENTING CELL; CELL DEATH; CELL MEMBRANE; CHEMISTRY; CYTOLOGY; ENDOPLASMIC RETICULUM; GENETICS; METABOLISM; MOUSE; PHOSPHORYLATION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGEN-PRESENTING CELLS; APOPTOSIS; BIOMARKERS; CALRETICULIN; CELL DEATH; CELL MEMBRANE; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; EPITOPES; EUKARYOTIC INITIATION FACTOR-2; HEAT-SHOCK PROTEINS; HUMANS; MICE; PHOSPHORYLATION; PROTEIN BIOSYNTHESIS; SIGNAL TRANSDUCTION;

EID: 84938206653     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2015.02.004     Document Type: Review

References (121)

1. Kepp O., Galluzzi L., Martins I., Schlemmer F., Adjemian S., Michaud M., et al. Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev 2011, 30:61-69.
2. Kroemer G., Galluzzi L., Kepp O., Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013, 31:51-72.
3. Krysko D.V., Garg A.D., Kaczmarek A., Krysko O., Agostinis P., Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 2012, 12:860-875.
4. Obeid M., Tesniere A., Ghiringhelli F., Fimia G.M., Apetoh L., Perfettini J.L., et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007, 13:54-61.
5. Michaud M., Martins I., Sukkurwala A.Q., Adjemian S., Ma Y., Pellegatti P., et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011, 334:1573-1577.
6. Aranda F., Bloy N., Pesquet J., Petit B., Chaba K., Sauvat A., et al. Immune-dependent antineoplastic effects of cisplatin plus pyridoxine in non-small-cell lung cancer. Oncogene 2014.
7. Casares N., Pequignot M.O., Tesniere A., Ghiringhelli F., Roux S., Chaput N., et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005, 202:1691-1701.
8. Ma Y., Aymeric L., Locher C., Mattarollo S.R., Delahaye N.F., Pereira P., et al. Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med 2011, 208:491-503.
9. Apetoh L., Ghiringhelli F., Tesniere A., Obeid M., Ortiz C., Criollo A., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007, 13:1050-1059.
10. Ghiringhelli F., Apetoh L., Tesniere A., Aymeric L., Ma Y., Ortiz C., et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009, 15:1170-1178.
11. Fridman W.H., Pages F., Sautes-Fridman C., Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012, 12:298-306.
12. Senovilla L., Vacchelli E., Galon J., Adjemian S., Eggermont A., Fridman W.H., et al. Trial watch: prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology 2012, 1:1323-1343.
13. Kepp O., Senovilla L., Vitale I., Vacchelli E., Adjemian S., Agostinis P., et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology 2014, 3.
14. Panaretakis T., Kepp O., Brockmeier U., Tesniere A., Bjorklund A.C., Chapman D.C., et al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J 2009, 28:578-590.
15. Martins I., Wang Y., Michaud M., Ma Y., Sukkurwala A.Q., Shen S., et al. Molecular mechanisms of ATP secretion during immunogenic cell death. Cell Death Differ 2014, 21:79-91.
16. Martins I., Tesniere A., Kepp O., Michaud M., Schlemmer F., Senovilla L., et al. Chemotherapy induces ATP release from tumor cells. Cell Cycle 2009, 8:3723-3728.
17. Yamazaki T., Hannani D., Poirier-Colame V., Ladoire S., Locher C., Sistigu A., et al. Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists. Cell Death Differ 2014, 21:69-78.
18. Thorburn J., Horita H., Redzic J., Hansen K., Frankel A.E., Thorburn A. Autophagy regulates selective HMGB1 release in tumor cells that are destined to die. Cell Death Differ 2009, 16:175-183.
19. Kepp O., Menger L., Vacchelli E., Locher C., Adjemian S., Yamazaki T., et al. Crosstalk between ER stress and immunogenic cell death. Cytokine Growth Factor Rev 2013, 24:311-318.
20. Dudek A.M., Garg A.D., Krysko D.V., De Ruysscher D., Agostinis P. Inducers of immunogenic cancer cell death. Cytokine Growth Factor Rev 2013, 24:319-333.
21. Bloy N., Pol J., Manic G., Vitale I., Eggermont A., Galon J., et al. Trial Watch: radioimmunotherapy for oncological indications. Oncoimmunology 2014, 3.
22. Vacchelli E., Vitale I., Tartour E., Eggermont A., Sautes-Fridman C., Galon J., et al. Trial Watch: anticancer radioimmunotherapy. Oncoimmunology 2013, 2:e25595.
23. Formenti S.C., Demaria S. Radiation therapy to convert the tumor into an in situ vaccine. Int J Radiat Oncol Biol Phys 2012, 84:879-880.
24. Galluzzi L., Kepp O., Kroemer G. Immunogenic cell death in radiation therapy. Oncoimmunology 2013, 2:e26536.
25. Garg A.D., Krysko D.V., Vandenabeele P., Agostinis P. Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin. Cancer Immunol Immunother 2012, 61:215-221.
26. Galluzzi L., Kepp O., Kroemer G. Enlightening the impact of immunogenic cell death in photodynamic cancer therapy. EMBO J 2012, 31:1055-1057.
27. Garg A.D., Krysko D.V., Verfaillie T., Kaczmarek A., Ferreira G.B., Marysael T., et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J 2012, 31:1062-1079.
28. Korbelik M., Sun J., Cecic I. Photodynamic therapy-induced cell surface expression and release of heat shock proteins: relevance for tumor response. Cancer Res 2005, 65:1018-1026.
29. Schiavoni G., Sistigu A., Valentini M., Mattei F., Sestili P., Spadaro F., et al. Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res 2011, 71:768-778.
30. Vacchelli E., Aranda F., Eggermont A., Galon J., Sautes-Fridman C., Cremer I., et al. Trial Watch: chemotherapy with immunogenic cell death inducers. Oncoimmunology 2014, 3:e27878.
31. Vacchelli E., Senovilla L., Eggermont A., Fridman W.H., Galon J., Zitvogel L., et al. Trial watch: chemotherapy with immunogenic cell death inducers. Oncoimmunology 2013, 2:e23510.
32. Tesniere A., Schlemmer F., Boige V., Kepp O., Martins I., Ghiringhelli F., et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2010, 29:482-491.
33. Martins I., Kepp O., Schlemmer F., Adjemian S., Tailler M., Shen S., et al. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene 2011, 30:1147-1158.
34. Kroemer G., Marino G., Levine B. Autophagy and the integrated stress response. Mol Cell 2010, 40:280-293.
35. Galluzzi L., Kepp O., Trojel-Hansen C., Kroemer G. Mitochondrial control of cellular life, stress, and death. Circ Res 2012, 111:1198-1207.
36. Garg A.D., Martin S., Golab J., Agostinis P. Danger signalling during cancer cell death: origins, plasticity and regulation. Cell Death Differ 2014, 21:26-38.
37. Hou W., Zhang Q., Yan Z., Chen R., Zeh Iii H.J., Kang R., et al. Strange attractors: DAMPs and autophagy link tumor cell death and immunity. Cell Death Dis 2013, 4:e966.
38. Krysko O., Love Aaes T., Bachert C., Vandenabeele P., Krysko D.V. Many faces of DAMPs in cancer therapy. Cell Death Dis 2013, 4:e631.
39. Brenner C., Galluzzi L., Kepp O., Kroemer G. Decoding cell death signals in liver inflammation. J Hepatol 2013, 59:583-594.
40. Spisek R., Charalambous A., Mazumder A., Vesole D.H., Jagannath S., Dhodapkar M.V. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood 2007, 109:4839-4845.
41. Aguilera R., Saffie C., Tittarelli A., Gonzalez F.E., Ramirez M., Reyes D., et al. Heat-shock induction of tumor-derived danger signals mediates rapid monocyte differentiation into clinically effective dendritic cells. Clin Cancer Res 2011, 17:2474-2483.
42. Lv L.H., Wan Y.L., Lin Y., Zhang W., Yang M., Li G.L., et al. Anticancer drugs cause release of exosomes with heat shock proteins from human hepatocellular carcinoma cells that elicit effective natural killer cell antitumor responses in vitro. J Biol Chem 2012, 287:15874-15885.
43. Vega V.L., Rodriguez-Silva M., Frey T., Gehrmann M., Diaz J.C., Steinem C., et al. Hsp70 translocates into the plasma membrane after stress and is released into the extracellular environment in a membrane-associated form that activates macrophages. J Immunol 2008, 180:4299-4307.
44. Korbelik M., Banath J., Sun J., Canals D., Hannun Y.A., Separovic D. Ceramide and sphingosine-1-phosphate act as photodynamic therapy-elicited damage-associated molecular patterns: cell surface exposure. Int Immunopharmacol 2014, 20:359-365.
45. Galluzzi L., Kepp O., Kroemer G. Mitochondria: master regulators of danger signalling. Nat Rev Mol Cell Biol 2012, 13:780-788.
46. Krysko D.V., Agostinis P., Krysko O., Garg A.D., Bachert C., Lambrecht B.N., et al. Emerging role of damage-associated molecular patterns derived from mitochondria in inflammation. Trends Immunol 2011, 32:157-164.
47. Zhang Q., Raoof M., Chen Y., Sumi Y., Sursal T., Junger W., et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010, 464:104-107.
48. Martinon F., Petrilli V., Mayor A., Tardivel A., Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440:237-241.
49. Ahrens S., Zelenay S., Sancho D., Hanc P., Kjaer S., Feest C., et al. F-actin is an evolutionarily conserved damage-associated molecular pattern recognized by DNGR-1, a receptor for dead cells. Immunity 2012, 36:635-645.
50. Taylor K.R., Trowbridge J.M., Rudisill J.A., Termeer C.C., Simon J.C., Gallo R.L. Hyaluronan fragments stimulate endothelial recognition of injury through TLR4. J Biol Chem 2004, 279:17079-17084.
51. Scheibner K.A., Lutz M.A., Boodoo S., Fenton M.J., Powell J.D., Horton M.R. Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J Immunol 2006, 177:1272-1281.
52. Garg A.D., Dudek A.M., Agostinis P. Autophagy-dependent suppression of cancer immunogenicity and effector mechanisms of innate and adaptive immunity. Oncoimmunology 2013, 2:e26260.
53. Vacchelli E., Vitale I., Eggermont A., Fridman W.H., Fucikova J., Cremer I., et al. Trial watch: dendritic cell-based interventions for cancer therapy. Oncoimmunology 2013, 2:e25771.
54. Schreibelt G., Bol K.F., Aarntzen E.H., Gerritsen W.R., Punt C.J., Figdor C.G., et al. Importance of helper T-cell activation in dendritic cell-based anticancer immunotherapy. Oncoimmunology 2013, 2:e24440.
55. Jeannin P., Jaillon S., Delneste Y. Pattern recognition receptors in the immune response against dying cells. Curr Opin Immunol 2008, 20:530-537.
56. Ma Y., Adjemian S., Yang H., Catani J.P., Hannani D., Martins I., et al. ATP-dependent recruitment, survival and differentiation of dendritic cell precursors in the tumor bed after anticancer chemotherapy. Oncoimmunology 2013, 2:e24568.
57. Elliott M.R., Chekeni F.B., Trampont P.C., Lazarowski E.R., Kadl A., Walk S.F., et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 2009, 461:282-286.
58. Ma Y., Adjemian S., Mattarollo S.R., Yamazaki T., Aymeric L., Yang H., et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 2013, 38:729-741.
59. McDonald B., Pittman K., Menezes G.B., Hirota S.A., Slaba I., Waterhouse C.C., et al. Intravascular danger signals guide neutrophils to sites of sterile inflammation. Science 2010, 330:362-366.
60. Zitvogel L., Kepp O., Galluzzi L., Kroemer G. Inflammasomes in carcinogenesis and anticancer immune responses. Nat Immunol 2012, 13:343-351.
61. Di Virgilio F. Liaisons dangereuses: P2X(7) and the inflammasome. Trends Pharmacol Sci 2007, 28:465-472.
62. Riteau N., Baron L., Villeret B., Guillou N., Savigny F., Ryffel B., et al. ATP release and purinergic signaling: a common pathway for particle-mediated inflammasome activation. Cell Death Dis 2012, 3:e403.
63. Scaffidi P., Misteli T., Bianchi M.E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002, 418:191-195.
64. Bianchi M.E., Manfredi A.A. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol Rev 2007, 220:35-46.
65. Aranda F., Vacchelli E., Obrist F., Eggermont A., Galon J., Sautes-Fridman C., et al. Trial Watch: toll-like receptor agonists in oncological indications. Oncoimmunology 2014, 3:e29179.
66. Spel L., Boelens J.J., Nierkens S., Boes M. Antitumor immune responses mediated by dendritic cells: how signals derived from dying cancer cells drive antigen cross-presentation. Oncoimmunology 2013, 2:e26403.
67. Bravo R., Parra V., Gatica D., Rodriguez A.E., Torrealba N., Paredes F., et al. Endoplasmic reticulum and the unfolded protein response: dynamics and metabolic integration. Int Rev Cell Mol Biol 2013, 301:215-290.
68. Hetz C., Chevet E., Harding H.P. Targeting the unfolded protein response in disease. Nat Rev Drug Discov 2013, 12:703-719.
69. Harding H.P., Zhang Y., Ron D. Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. Nature 1999, 397:271-274.
70. Ernst V., Levin D.H., Leroux A., London I.M. Site-specific phosphorylation of the alpha subunit of eukaryotic initiation factor eIF-2 by the heme-regulated and double-stranded RNA-activated eIF-2 alpha kinases from rabbit reticulocyte lysates. Proc Natl Acad Sci USA 1980, 77:1286-1290.
71. Matts R.L., Levin D.H., London I.M. Effect of phosphorylation of the alpha-subunit of eukaryotic initiation factor 2 on the function of reversing factor in the initiation of protein synthesis. Proc Natl Acad Sci USA 1983, 80:2559-2563.
72. Siekierka J., Manne V., Ochoa S. Mechanism of translational control by partial phosphorylation of the alpha subunit of eukaryotic initiation factor 2. Proc Natl Acad Sci USA 1984, 81:352-356.
73. Sarnow P. Translation of glucose-regulated protein 78/immunoglobulin heavy-chain binding protein mRNA is increased in poliovirus-infected cells at a time when cap-dependent translation of cellular mRNAs is inhibited. Proc Natl Acad Sci USA 1989, 86:5795-5799.
74. Vattem K.M., Wek R.C. Reinitiation involving upstream ORFs regulates ATF4 mRNA translation in mammalian cells. Proc Natl Acad Sci USA 2004, 101:11269-11274.
75. Han D., Lerner A.G., Vande Walle L., Upton J.P., Xu W., Hagen A., et al. IRE1alpha kinase activation modes control alternate endoribonuclease outputs to determine divergent cell fates. Cell 2009, 138:562-575.
76. Hollien J., Lin J.H., Li H., Stevens N., Walter P., Weissman J.S. Regulated Ire1-dependent decay of messenger RNAs in mammalian cells. J Cell Biol 2009, 186:323-331.
77. Hollien J., Weissman J.S. Decay of endoplasmic reticulum-localized mRNAs during the unfolded protein response. Science 2006, 313:104-107.
78. Harding H.P., Zhang Y., Zeng H., Novoa I., Lu P.D., Calfon M., et al. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol Cell 2003, 11:619-633.
79. Xu X., Gupta S., Hu W., McGrath B.C., Cavener D.R. Hyperthermia induces the ER stress pathway. PLoS ONE 2011, 6:e23740.
80. Shellman Y.G., Howe W.R., Miller L.A., Goldstein N.B., Pacheco T.R., Mahajan R.L., et al. Hyperthermia induces endoplasmic reticulum-mediated apoptosis in melanoma and non-melanoma skin cancer cells. J Investig Dermatol 2008, 128:949-956.
81. Price B.D., Mannheim-Rodman L.A., Calderwood S.K. Brefeldin A, thapsigargin, and AIF4-stimulate the accumulation of GRP78 mRNA in a cycloheximide dependent manner, whilst induction by hypoxia is independent of protein synthesis. J Cell Physiol 1992, 152:545-552.
82. Senovilla L., Vitale I., Martins I., Tailler M., Pailleret C., Michaud M., et al. An immunosurveillance mechanism controls cancer cell ploidy. Science 2012, 337:1678-1684.
83. Vitale I., Galluzzi L., Senovilla L., Criollo A., Jemaa M., Castedo M., et al. Illicit survival of cancer cells during polyploidization and depolyploidization. Cell Death Differ 2011, 18:1403-1413.
84. Vitale I., Galluzzi L., Castedo M., Kroemer G. Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol 2011, 12:385-392.
85. Ernst V., Levin D.H., London I.M. In situ phosphorylation of the alpha subunit of eukaryotic initiation factor 2 in reticulocyte lysates inhibited by heme deficiency, double-stranded RNA, oxidized glutathione, or the heme-regulated protein kinase. Proc Natl Acad Sci USA 1979, 76:2118-2122.
86. Galluzzi L., Kepp O., Morselli E., Vitale I., Senovilla L., Pinti M., et al. Viral strategies for the evasion of immunogenic cell death. J Intern Med 2010, 267:526-542.
87. Farrell P.J., Balkow K., Hunt T., Jackson R.J., Trachsel H. Phosphorylation of initiation factor elF-2 and the control of reticulocyte protein synthesis. Cell 1977, 11:187-200.
88. Meurs E., Chong K., Galabru J., Thomas N.S., Kerr I.M., Williams B.R., et al. Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon. Cell 1990, 62:379-390.
89. Galluzzi L., Kepp O., Vander Heiden M.G., Kroemer G. Metabolic targets for cancer therapy. Nat Rev Drug Discov 2013, 12:829-846.
90. Tzamarias D., Thireos G. Evidence that the GCN2 protein kinase regulates reinitiation by yeast ribosomes. EMBO J 1988, 7:3547-3551.
91. Roussou I., Thireos G., Hauge B.M. Transcriptional-translational regulatory circuit in Saccharomyces cerevisiae which involves the GCN4 transcriptional activator and the GCN2 protein kinase. Mol Cell Biol 1988, 8:2132-2139.
92. Novoa I., Zeng H., Harding H.P., Ron D. Feedback inhibition of the unfolded protein response by GADD34-mediated dephosphorylation of eIF2alpha. J Cell Biol 2001, 153:1011-1022.
93. Xu C., Bailly-Maitre B., Reed J.C. Endoplasmic reticulum stress: cell life and death decisions. J Clin Investig 2005, 115:2656-2664.
94. Ma Y., Hendershot L.M. Delineation of a negative feedback regulatory loop that controls protein translation during endoplasmic reticulum stress. J Biol Chem 2003, 278:34864-34873.
95. Blais J.D., Filipenko V., Bi M., Harding H.P., Ron D., Koumenis C., et al. Activating transcription factor 4 is translationally regulated by hypoxic stress. Mol Cell Biol 2004, 24:7469-7482.
96. Tabas I., Ron D. Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat Cell Biol 2011, 13:184-190.
97. Todd D.J., Lee A.H., Glimcher L.H. The endoplasmic reticulum stress response in immunity and autoimmunity. Nat Rev Immunol 2008, 8:663-674.
98. Galluzzi L., Bravo-San Pedro J.M., Kroemer G. Organelle-specific initiation of cell death. Nat Cell Biol 2014, 16:728-736.
99. Boyce M., Bryant K.F., Jousse C., Long K., Harding H.P., Scheuner D., et al. A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. Science 2005, 307:935-939.
100. Han J., Back S.H., Hur J., Lin Y.H., Gildersleeve R., Shan J., et al. ER-stress-induced transcriptional regulation increases protein synthesis leading to cell death. Nat Cell Biol 2013, 15:481-490.
101. Rzymski T., Milani M., Pike L., Buffa F., Mellor H.R., Winchester L., et al. Regulation of autophagy by ATF4 in response to severe hypoxia. Oncogene 2010, 29:4424-4435.
102. B'Chir W., Maurin A.C., Carraro V., Averous J., Jousse C., Muranishi Y., et al. The eIF2alpha/ATF4 pathway is essential for stress-induced autophagy gene expression. Nucleic Acids Res 2013, 41:7683-7699.
103. Murtha-Riel P., Davies M.V., Scherer B.J., Choi S.Y., Hershey J.W., Kaufman R.J. Expression of a phosphorylation-resistant eukaryotic initiation factor 2 alpha-subunit mitigates heat shock inhibition of protein synthesis. J Biol Chem 1993, 268:12946-12951.
104. Scheuner D., Song B., McEwen E., Liu C., Laybutt R., Gillespie P., et al. Translational control is required for the unfolded protein response and in vivo glucose homeostasis. Mol Cell 2001, 7:1165-1176.
105. Talloczy Z., Jiang W., Virgin H.W.T., Leib D.A., Scheuner D., Kaufman R.J., et al. Regulation of starvation- and virus-induced autophagy by the eIF2alpha kinase signaling pathway. Proc Natl Acad Sci USA 2002, 99:190-195.
106. Talloczy Z., Virgin H.W.T., Levine B. PKR-dependent autophagic degradation of herpes simplex virus type 1. Autophagy 2006, 2:24-29.
107. Niso-Santano M., Shen S., Adjemian S., Malik S.A., Marino G., Lachkar S., et al. Direct interaction between STAT3 and EIF2AK2 controls fatty acid-induced autophagy. Autophagy 2013, 9:415-417.
108. Shen S., Niso-Santano M., Adjemian S., Takehara T., Malik S.A., Minoux H., et al. Cytoplasmic STAT3 represses autophagy by inhibiting PKR activity. Mol Cell 2012, 48:667-680.
109. Jiang H.Y., Wek S.A., McGrath B.C., Scheuner D., Kaufman R.J., Cavener D.R., et al. Phosphorylation of the alpha subunit of eukaryotic initiation factor 2 is required for activation of NF-kappaB in response to diverse cellular stresses. Mol Cell Biol 2003, 23:5651-5663.
110. Jiang H.Y., Wek R.C. GCN2 phosphorylation of eIF2alpha activates NF-kappaB in response to UV irradiation. Biochem J 2005, 385:371-380.
111. Cullinan S.B., Zhang D., Hannink M., Arvisais E., Kaufman R.J., Diehl J.A. Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival. Mol Cell Biol 2003, 23:7198-7209.
112. Cullinan S.B., Diehl J.A. PERK-dependent activation of Nrf2 contributes to redox homeostasis and cell survival following endoplasmic reticulum stress. J Biol Chem 2004, 279:20108-20117.
113. Galluzzi L., Bravo-San Pedro J.M., Vitale I., Aaronson S.A., Abrams J.M., Adam D., et al. Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. Cell Death Differ 2015, 22(1):58-73.
114. Galluzzi L., Vitale I., Abrams J.M., Alnemri E.S., Baehrecke E.H., Blagosklonny M.V., et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ 2012, 19:107-120.
115. Solimini N.L., Luo J., Elledge S.J. Non-oncogene addiction and the stress phenotype of cancer cells. Cell 2007, 130:986-988.
116. Atkins C., Liu Q., Minthorn E., Zhang S.Y., Figueroa D.J., Moss K., et al. Characterization of a novel PERK kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 2013, 73:1993-2002.
117. Kardosh A., Golden E.B., Pyrko P., Uddin J., Hofman F.M., Chen T.C., et al. Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib. Cancer Res 2008, 68:843-851.
118. Sukkurwala A.Q., Martins I., Wang Y., Schlemmer F., Ruckenstuhl C., Durchschlag M., et al. Immunogenic calreticulin exposure occurs through a phylogenetically conserved stress pathway involving the chemokine CXCL8. Cell Death Differ 2014, 21:59-68.
119. Cirone M., Garufi A., Di Renzo L., Granato M., Faggioni A., D'Orazi G. Zinc supplementation is required for the cytotoxic and immunogenic effects of chemotherapy in chemoresistant p53-functionally deficient cells. Oncoimmunology 2013, 2:e26198.
120. Zeng H., Chi H. The interplay between regulatory T cells and metabolism in immune regulation. Oncoimmunology 2013, 2:e26586.
121. Raja K.R., Hajek R. Contribution of regulatory T cells to immunosuppression and disease progression in multiple myeloma patients. Oncoimmunology 2013, 2:e25619.